In a second study, Kim et al. demonstrated that in vitro generation of WT1-specific cytotoxic T lymphocytes and subsequent transfer is a feasible therapeutic approach for the treatment of AML patients being at high risk of relapse after allo-HSCT [203]. Here, WT1 is linked to acute myeloid leukemia.